血清CYFRA21-1、CAR及IL-6联合检测对食管癌同步放化疗疗效的评估价值  

Evaluation value of combined detection of serum CYFRA21⁃1,CAR and IL⁃6 in the efficacy of concurrent chemoradiotherapy in esophageal cancer

作　　者：张震 王光明 刘玉平 常娟娟 ZHANG Zhen;WANG Guangming;LIU Yuping;CHANG Juanjuan(Ward 3,Department of Radiotherapy,Fuyang Cancer Hospital,Fuyang,Anhui,China,236000)

机构地区：[1]安徽省阜阳市肿瘤医院放疗科3病区,安徽阜阳236000

出　　处：《分子诊断与治疗杂志》2024年第6期1178-1182,共5页Journal of Molecular Diagnostics and Therapy

基　　金：安徽省教育厅自然基金重点项目(KJ2017A204)。

摘　　要：目的 探讨血清细胞角蛋白19片段抗原21-1(CYFRA21-1)、C反应蛋白与白蛋白比值(CAR)及白细胞介素-6(IL-6)联合检测对食管癌(EC)同步放化疗疗效的评估价值。方法 选取2020年1月7日至2023年7月20日期间安徽省阜阳市肿瘤医院放射治疗科收治的,经病理学确诊为EC的患者共计93例作为研究对象。根据治疗后肿瘤组织病变情况分为治疗有效组(n=62)与治疗无效组(n=31)。比较两组患者临床资料及实验室指标,采用多因素Logistic分析血清CYFRA21-1、CAR及IL-6与EC同步放化疗疗效的相关性,绘制受试者工作特性曲线(ROC)评估血清三者联合检测对EC同步放化疗疗效的诊断价值。结果 两组患者的年龄、淋巴结转移、临床分期、以及血清CYFRA21-1、CAR和IL-6表达水平比较,差异均具有统计学意义(P<0.05);多因素Logistic回归分析显示年龄的增加、有淋巴结转移、临床分期为Ⅲ期、血清CYFRA21-1、CAR及IL-6表达水平的升高均为影响EC同步放化疗效的独立危险因素(P<0.05)。ROC曲线显示,血清CYFRA21-1、CAR、IL-6以及三者联合检测曲线下面积为0.989、0.726、0.727以及0.995。结论 血清CYFRA21-1、CAR及IL-6均能有效预测EC同步放化疗疗效,且三者联用预测价值更高。Objective To evaluate the efficacy of simultaneous chemoradiotherapy in esophageal carcinoma(EC)with serum cytokeratin 19 fragment antigen 21-1(CYFRA21-1),C-reactive protein to albumin ratio(CAR)and interleukin-6(IL-6).Methods A total of 93 patients diagnosed with esophageal cancer by pa-thology were selected as the study subjects from January 7,2020 to July 20,2023 in the Radiotherapy depart-ment at Fuyang Cancer Hospital,Anhui Province.Based on the pathological changes of tumor tissues after treat-ment,they were divided into an effective group(n=62)and an ineffective group(n=31).The clinical data and laboratory indicators of the two groups were compared,and the correlation between serum CYFRA21-1,CAR and IL-6 and the efficacy of concurrent chemoradiotherapy for esophageal cancer was analyzed using multivari-ate logistic analysis.A receiver operating characteristic curve(ROC)was drawn to evaluate the diagnostic value of the combined detection of serum CYFRA21-1,CAR and IL-6 on the efficacy of concurrent chemoradio-therapy for esophageal cancer.Results Two groups of patients were compared based on age,lymph node me-tastasis,clinical stage,and serum levels of CYFRA21-1,CAR,and IL-6.The differences were statistically sig-nificant(P<0.05).Multivariate logistic regression analysis showed that increasing age,lymph node metastasis,clinical stageⅢ,and higher serum levels of CYFRA21-1,CAR,and IL-6 were all independent risk factors af-fecting the efficacy of concurrent chemoradiotherapy for EC(P<0.05).The ROC curve showed that the area un-der the curve for serum CYFRA21-1,CAR,IL-6,and the combined detection of the three were 0.989,0.726,0.727 and 0.995,respectively.Conclusion Serum CYFRA21-1,CAR,and IL-6 can effectively predict the ef-ficacy of concurrent chemoradiotherapy for esophageal cancer.The combined use of the three markers has a higher predictive value.

关 键 词：血清细胞角蛋白19 C反应蛋白与白蛋白比值 白细胞介素-6 

分 类 号：R735.1[医药卫生—肿瘤]